Viking Therapeutics (VKTX) Gains from Sales and Divestitures (2016 - 2025)
Historic Gains from Sales and Divestitures for Viking Therapeutics (VKTX) over the last 11 years, with Q4 2025 value amounting to $854220.0.
- Viking Therapeutics' Gains from Sales and Divestitures fell 4492.47% to $854220.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $854220.0, marking a year-over-year decrease of 4492.47%. This contributed to the annual value of $854220.0 for FY2025, which is 4492.47% down from last year.
- As of Q4 2025, Viking Therapeutics' Gains from Sales and Divestitures stood at $854220.0, which was down 4492.47% from $744017.0 recorded in Q3 2025.
- In the past 5 years, Viking Therapeutics' Gains from Sales and Divestitures registered a high of $1.6 million during Q3 2024, and its lowest value of $192229.0 during Q1 2021.
- For the 5-year period, Viking Therapeutics' Gains from Sales and Divestitures averaged around $662934.5, with its median value being $668015.0 (2025).
- Per our database at Business Quant, Viking Therapeutics' Gains from Sales and Divestitures surged by 27672.02% in 2021 and then crashed by 5202.99% in 2025.
- Quarter analysis of 5 years shows Viking Therapeutics' Gains from Sales and Divestitures stood at $270063.0 in 2021, then skyrocketed by 51.66% to $409569.0 in 2022, then soared by 91.69% to $785105.0 in 2023, then skyrocketed by 97.55% to $1.6 million in 2024, then tumbled by 44.92% to $854220.0 in 2025.
- Its last three reported values are $854220.0 in Q4 2025, $744017.0 for Q3 2025, and $668015.0 during Q2 2025.